Brit J Cancer:晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应

2020-01-04 AlexYang MedSci原创

在转移尿路上皮癌(mUC)中,与免疫检查点抑制剂(ICIs)响应相关的可预测生物标记仍旧缺乏。最近,有研究人员在mUC中调查分析了与ICIs响应有关的基因组和临床因素。研究包括了62名进行了ICI治疗的mUC患者,并进行了肿瘤靶向测序。研究人员调查了候选生物标记与临床益处(CB,肿瘤大小的任何客观上的减少)和非临床益处(NCB,肿瘤大小没有变化或者肿瘤大小增加)。研究还包括了一个由39名紫杉烷治疗

在转移尿路上皮癌(mUC)中,与免疫检查点抑制剂(ICIs)响应相关的可预测生物标记仍旧缺乏。最近,有研究人员在mUC中调查分析了与ICIs响应有关的基因组和临床因素。

研究包括了62名进行了ICI治疗的mUC患者,并进行了肿瘤靶向测序。研究人员调查了候选生物标记与临床益处(CB,肿瘤大小的任何客观上的减少)和非临床益处(NCB,肿瘤大小没有变化或者肿瘤大小增加)。研究还包括了一个由39名紫杉烷治疗的mUC患者组成的比较群体。研究发现,在ICI群体单变量分析中,9个临床和7个基因组因素与临床结果相关。在其中的16个因素中,多变量分析表明中性粒细胞与淋巴细胞比值(NLR)≥5(OR=0.12, 95% CI, 0.01-1.15)、内脏转移(OR=0.05, 95% CI, 0.01-0.43)和单核苷酸变异(SNV)数量<10(OR=0.04, 95% CI, 0.006-0.27)鉴定为ICI的NCB独立预测因子(c-statistic=0.90)。在紫杉烷治疗的群体中,16个变量中与任何一个均与临床益处无关。

最后,研究人员指出,他们的3因素模型包括了基因组(SNV数>9)和临床(NLR<5,不包括内脏转移)变量,能够预测对mUC患者中ICI的受益情况,但是对紫杉烷治疗没有预测价值。研究人员也指出他们的结果还需要进一步的外部验证,才能在常规临床护理中使用。

原始出处:

Amin H. Nassar, Kent W. Mouw, Opeyemi Jegede et al. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Brit J Cancer. 20 Dec 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710209, encodeId=db431e1020926, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 09 22:07:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255043, encodeId=96bf1255043db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440247, encodeId=6e46144024e7a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59825, encryptionId=89795982594, topicName=晚期尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36294710956, createdName=1249894fm74暂无昵称, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539348, encodeId=554e1539348ad, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047754, encodeId=f624104e75472, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jan 04 17:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710209, encodeId=db431e1020926, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 09 22:07:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255043, encodeId=96bf1255043db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440247, encodeId=6e46144024e7a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59825, encryptionId=89795982594, topicName=晚期尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36294710956, createdName=1249894fm74暂无昵称, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539348, encodeId=554e1539348ad, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047754, encodeId=f624104e75472, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jan 04 17:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-06 smartjoy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710209, encodeId=db431e1020926, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 09 22:07:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255043, encodeId=96bf1255043db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440247, encodeId=6e46144024e7a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59825, encryptionId=89795982594, topicName=晚期尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36294710956, createdName=1249894fm74暂无昵称, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539348, encodeId=554e1539348ad, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047754, encodeId=f624104e75472, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jan 04 17:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710209, encodeId=db431e1020926, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 09 22:07:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255043, encodeId=96bf1255043db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440247, encodeId=6e46144024e7a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59825, encryptionId=89795982594, topicName=晚期尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36294710956, createdName=1249894fm74暂无昵称, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539348, encodeId=554e1539348ad, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047754, encodeId=f624104e75472, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jan 04 17:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1710209, encodeId=db431e1020926, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 09 22:07:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255043, encodeId=96bf1255043db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440247, encodeId=6e46144024e7a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59825, encryptionId=89795982594, topicName=晚期尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36294710956, createdName=1249894fm74暂无昵称, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539348, encodeId=554e1539348ad, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Mon Jan 06 05:07:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047754, encodeId=f624104e75472, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Jan 04 17:07:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 CHANGE

    梅斯里提供了很多疾病的模型计算公式,赞一个!

    0

相关资讯

OLYMPUS试验的二次分析:UGN-101治疗尿路上皮癌的CR率高达59%

UroGen是一家临床阶段生物制药公司,致力于开发、解决泌尿学领域未满足的医疗需求,UroGen近日公布了关键的III期OLYMPUS试验的二次分析结果,该试验显示UGN-101(丝裂霉素)治疗不可切除的低级别上尿路上皮癌(UTUC)患者能够实现59%的完全缓解率(CR)。

Clinica Chimica Acta:术前淋巴细胞与单核细胞比值对上尿路上皮癌的预测价值

本研究的目的是探讨术前淋巴细胞单核细胞比 · 2019-08-08

-->

Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌,获得FDA批准

Astellas和Seattle Genetics宣布FDA加快了对Padcev(enfortumab vedotin-ejfv)的批准,用于治疗部分局部晚期或转移性尿路上皮癌的成年患者。具体来说,该靶向Nectin-4的抗体-药物偶联物(ADC)被指定用于先前在手术前后接受过PD-1/L1抑制剂和含铂化疗后局部晚期或转移性的患者。

Sci Rep:MB49尿路上皮癌模型中转移潜力增强

最近有数据表明患有基底/茎样膀胱癌(BC)亚型的患者倾向于患有转移性疾病,但是该结论尚未得到确认。最近,有研究人员报道了具有基底/茎样特性的小鼠MB49细胞系亚克隆在培养条件下的相关特征鉴定。研究发现,皮下植入S2和S4 MB49亚克隆到免疫感受态小鼠能够分别导致50%和80%的肺转移比例,然而,当利用亲代细胞进行移植时,没有小数发展为转移结果。S2和S4原发性和转移性肿瘤的细胞培养的基因分析阐释

Lancet Oncol:Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌

Ramucirumab联合多西他奇能显著提高铂类难治性晚期尿路上皮癌患者无进展生存率,但总体生存率没有显著改善

Sci Rep:膀胱pT1尿路上皮癌腺性分化预测不良预后

最近,有研究人员评估了腺性分化(GD)对膀胱pT1尿路上皮癌(UC)的肿瘤复发和恶化的影响。研究人员对具有膀胱尿路上皮癌腺性分化(UCGD)的82名患者进行了回顾性的分析,这些患者被诊断为病理性pT1;166名不具有组织性变异的膀胱pT1 UC患者作为对照。研究发现,UCGD患者更可能具有更高的复发率(P=0.002)和更高的恶化率(P<0.001)。更多的是,UCGD和5年总生存(OS)(